To a T: Testosterone Supplementation and Reducing Treatment Time in Stroke

Subscribe on iTunes

Originally aired April 30, 2014: Cardiovascular risk and testosterone supplementation, reducing time to treatment in acute ischemic stroke.

Fahad and Amol want you to:

1. Recognize that observational evidence suggests that testosterone supplementation is significantly associated with cardiovascular events and mortality.

2. Understand that a national quality improvement initiative was associated with reduced treatment times for stroke and improved clinical outcomes.

Continuing Medical Education

Internists can receive 0.5 hours of Continuing Medical Education credit for each podcast they listen to through the Canadian Society of Internal Medicine (MOC Category 1) and the American Medical Association (PRA Category 1). To receive CME credit for listening to this podcast, please click here to fill out our Evaluation and Impact Assessment Form.

The papers

Rebecca Vigen et al. Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels. JAMA. 2013;310(17):1829-183.

Gregg C Fonarow et al. Door-to-Needle Times for Tissue Plasminogen Activator Administration and Clinical Outcomes in Acute Ischemic Stroke Before and After a Quality Improvement Initiative. JAMA. 2014;311(16):1632-1640.

Good stuff

Fahad – How Doctors Die: Showing Others the Way, Dan Gorenstein, New York Times, November 19, 2013. 

Amol – Jonas Salk: Good at Virology, Bad at Economics, Brian Palmer, Slate.com, April 13, 2014. 

Leave a Comment

Your email address will not be published. Required fields are marked *

Republish this article

Republish this article on your website under the creative commons licence.

Learn more